RxDoctor Payments DataLook up a doctor →

Shahram Naiem, MD

Cardiology · West Hollywood, CANPI 1477659266

Payments from drug & device makers

$15,369in general payments, 2019–2025

Across 805 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • Novartis$2K
  • Johnson & Johnson$2K
  • Amgen$1K
  • Pfizer$833
  • Sanofi-aventis U.S. LLC$812
  • plus $7K from 38 others

What the payments were for

  • Food & beverage$15,294100%
  • Education$750%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,369 in reported general payments places this provider in the 90th percentile of 156 cardiology providers in California.

See all cardiology providers in California

Medicare billing

Part B allowed, 2024
$788,876
Medicare patients
1,031
Services billed
5,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban402$391,904
XareltoRivaroxaban140$138,042
Repatha SureclickEvolocumab112$88,770
MultaqDronedarone Hcl42$57,062
EntrestoSacubitril/Valsartan55$51,970
Praluent PenAlirocumab23$24,363
FarxigaDapagliflozin Propanediol16$12,371
Repatha SyringeEvolocumab14$8,271
JardianceEmpagliflozin15$5,361
Icosapent Ethyl24$5,274
LivaloPitavastatin Calcium12$5,266
Pitavastatin Calcium36$3,443
Losartan Potassium304$3,298
Atorvastatin Calcium297$2,761
Amiodarone Hcl106$2,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$833$391,904402 claims
Johnson & JohnsonXarelto$1,775$138,042140 claims
Sanofi-aventis U.S. LLCMultaq$812$57,06242 claims
NovartisEntresto$1,889$51,97055 claims
AstraZenecaFarxiga$740$12,37116 claims
Boehringer IngelheimJardiance$308$5,36115 claims
Kowa Pharmaceuticals America, Inc.Livalo$56$5,26612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 156 cardiology providers in California.

Other cardiology in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →